- Home
- ALLO vs VACH Comparison
ALLO vs VACH Comparison
Compare ALLO & VACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- VACH
- Stock Information
- Founded
- ALLO 2017
- VACH 2023
- Country
- ALLO United States
- VACH United States
- Employees
- ALLO N/A
- VACH N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- VACH
- Sector
- ALLO Health Care
- VACH
- Exchange
- ALLO Nasdaq
- VACH NYSE
- Market Cap
- ALLO 338.9M
- VACH 321.3M
- IPO Year
- ALLO 2018
- VACH 2024
- Fundamental
- Price
- ALLO $1.55
- VACH $10.25
- Analyst Decision
- ALLO Strong Buy
- VACH
- Analyst Count
- ALLO 10
- VACH 0
- Target Price
- ALLO $9.66
- VACH N/A
- AVG Volume (30 Days)
- ALLO 2.6M
- VACH 116.9K
- Earning Date
- ALLO 05-12-2025
- VACH 01-01-0001
- Dividend Yield
- ALLO N/A
- VACH N/A
- EPS Growth
- ALLO N/A
- VACH N/A
- EPS
- ALLO N/A
- VACH 0.26
- Revenue
- ALLO $22,000.00
- VACH N/A
- Revenue This Year
- ALLO N/A
- VACH N/A
- Revenue Next Year
- ALLO $9.07
- VACH N/A
- P/E Ratio
- ALLO N/A
- VACH $39.95
- Revenue Growth
- ALLO N/A
- VACH N/A
- 52 Week Low
- ALLO $1.23
- VACH $9.95
- 52 Week High
- ALLO $3.78
- VACH $11.20
- Technical
- Relative Strength Index (RSI)
- ALLO 49.84
- VACH N/A
- Support Level
- ALLO $1.38
- VACH N/A
- Resistance Level
- ALLO $1.75
- VACH N/A
- Average True Range (ATR)
- ALLO 0.13
- VACH 0.00
- MACD
- ALLO 0.04
- VACH 0.00
- Stochastic Oscillator
- ALLO 61.54
- VACH 0.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About VACH VOYAGER ACQUISITION CORP.
Voyager Acquisition Corp is a blank check company.